|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While the exhaustion profiles of primary and recurrent GBM are comparable, TCR sequencing demonstrated a contracted repertoire in recurrent GBM, concomitant with an increased frequency of activated memory T cells in recurrent tumors.<i>Clin Cancer Res; 24(17); 4187-200.
|
29444930 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This approach, which is called TCR gene therapy, is being developed to target tumors and pathogens, and its clinical testing has commenced in patients with cancer.
|
20400962 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDR III IgH PCR has been confirmed as an efficient method for determining clonality in B-cell neoplasias.
|
10975394 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Abs that recognize these tumor-associated MHC-peptide complexes, with the same specificity as TCR, would therefore be valuable reagents for studying Ag presentation by tumor cells, for visualizing MHC-peptide complexes on cells, and eventually for developing new targeting agents for cancer immunotherapy.
|
12928363 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The TCR-beta gene rearrangement detected in this patient, confirmed with polymerase chain reaction (PCR) amplification of the TCR-gamma gene rearrangement, did not correlate with the presence of circulating Sezary cells or the increased risk of neoplasia.
|
7492785 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Early TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications.
|
15459015 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The application of human TCR in cancer immunotherapy has gained momentum with developments in tumor killing strategies using endogenous adaptive immune responses.
|
30919413 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In order to achieve broader application, an efficient method to identify TCR genes for an array of tumor antigens and HLA restriction elements is required.
|
29588318 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Defects in the CD3/TCR complex and impairment of T cell function are necessary for tumor evasion, but the underlying mechanisms are incompletely understood.
|
18713979 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data argue that TCR transgenes that contain CD28, and, thereby, may provide T cell costimulation in an immune-suppressive environment, represent candidate receptors to treat patients with tumors.
|
25320284 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene expression profile of tumors in regression shows abundance of activated tumor infiltrating T cells with a more diversified TCR repertoire in animals treated with GAd and anti-PD1 compared to anti-PD1.
|
31217437 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Human CD8+ T cells activated and expanded by TCR cross-linking and high-dose IL-2 acquire potent cytolytic ability against tumors and are a promising approach for immunotherapy of malignant diseases.
|
16339517 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Crosslineage T-cell receptor delta (TCR delta) rearrangements are widely used as tumor markers for the follow up of minimal residual disease in childhood B-precursor acute lymphoblastic leukemia (ALL) by polymerase chain reaction (PCR).
|
7606000 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vitro generation of tumor specific T cells that recognize a shared antigen of AML: molecular characterization of TCR genes.
|
16750565 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Initial clinical studies have demonstrated that TCR gene-engineered T cells could mediate tumor regression in vivo.
|
22178904 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
It is known that a clonal T-cell receptor (TCR) gene rearrangement is not found in this tumour.
|
10233275 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Rearrangements of immunoglobulin (Ig) and T cell receptor (TCR) genes provide a highly sensitive molecular marker for the detection of clonality in lymphoid lesions and allow the pathologist to (1) distinguish polyclonal from monoclonal lymphoid proliferations, (2) provide corroborative evidence for lineage when used in conjunction with immunophenotypic techniques, (3) differentiate clonal lymphoid lesions from poorly differentiated nonlymphoid neoplasms, and (4) assess residual disease at the molecular level.
|
2184975 |
1990 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
|
10384155 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We find that ALK+ and ALK- ALCL share common DNA methylation changes for genes involved in T cell differentiation and immune response, including TCR and CTLA-4, without an ALK-specific impact on tumor DNA methylation in gene promoters.
|
27705804 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings demonstrate that breast tumor-specific CTL clones can be generated through current technology and that a alpha/beta effector cell population operating through a HLA-unrestricted and TCR/CD3-independent pathway may be involved in the identification and killing of this tumor.
|
7929817 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Simultaneous detection of TCRA/D or TCRB breaks was achieved in a multicolor approach, which was further combined with detection of the T-cell-specific CD3 antigen in a multicolor FICTION (Fluorescence Immunophenotyping and Interphase Cytogenetics as a Tool for the Investigation of Neoplasm) assay.
|
12682631 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we demonstrate that Fab fragments of UCHT1, which only bind monovalently to the γδ TCR, also enhanced tumor killing by expanded human Vγ9Vδ2 γδ T cells or pan-γδ T cells of the peripheral blood.
|
30038626 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumour-specific oligoprobes were developed against the single V1-J1 rearrangement of the delta T-cell receptor (TCR) gene in order to perform minimal residual disease (MRD) studies.
|
7669677 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In view of these findings, failure to detect rearrangements of TCR genes by Southern blot analyses is not necessarily inconsistent with malignant lymphocytic proliferations in T-lineage neoplasia.
|
3258126 |
1988 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dual rearrangement of both immunoglobulin and T-cell receptor (TCR) genes has been described in up to 30% of precursor lymphoid neoplasms, but this phenomenon occurs rarely in lymphomas with a mature phenotype.
|
7943530 |
1994 |